Baxdrostat for hypertension

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 3 registered trials.

Why this status

  1. 13 Sep 2023: Trial registered, NCT06034743
  2. 22 Nov 2023: Trial started, NCT06034743
  3. 13 Dec 2023: Trial registered, NCT06168409
  4. 1 Mar 2024: Trial started, NCT06168409
  5. 3 Apr 2024: Trial registered, NCT06344104
  6. 8 Apr 2024: Trial started, NCT06344104

The trials

NCT06034743: A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension

State
Completed
Phase
Phase 3
People
796 taking part
Started
22 Nov 2023
Primary completion
21 May 2025
Arms
2 mg baxdrostat, 1 mg baxdrostat
Results
Posted on the registry
Papers
doi:10.1038/s41440-025-02297-7, doi:10.1056/nejmoa2507109, doi:10.1093/ajh/hpae051
  1. 13 Sep 2023: Trial registered
  2. 22 Nov 2023: Trial started
  3. 10 Oct 2025: Trial completed
  4. 30 Jul 2026: Trial results posted

NCT06344104: A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension

State
Completed
Phase
Phase 3
People
326 taking part
Started
8 Apr 2024
Primary completion
24 Nov 2025
Arms
2 mg baxdrostat, 1 mg baxdrostat
Results
None posted
Papers
doi:10.1038/s41440-025-02297-7, doi:10.2215/cjn.0000001266
  1. 3 Apr 2024: Trial registered
  2. 8 Apr 2024: Trial started
  3. 3 Apr 2026: Trial completed

How the status changed

  1. 16 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as Baxfendy, CIN-107 2 mg dosing, CIN-107 4 mg dosing, CIN-107 8 mg dosing.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.